The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.
Company Info
| CEO | Michel Vounatsos |
| CEO Title | Chief Executive Officer & Director |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Cambridge, MA |
| Website | www.biogen.com |
| Years on Fortune 500 List | 8 |
| Employees | 7,400 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $11,449 |
| Profits ($M) | $3,702.8 |
| Assets ($M) | $22,877 |
| Total Stockholder Equity ($M) | $12,140 |
| Market Value — as of March 31, 2017 ($M) | $59,046 |
Profit Ratios
| Profit as % of Revenues | 32.3% |
| Profits as % of Assets | 16.2% |
| Profits as % of Stockholder Equity | 30.5% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 17 |
| EPS % Change (from 2015) | 10.4% |
| EPS % Change (5 year annual rate) | 27.4% |
| EPS % Change (10 year annual rate) | 39% |
Total Return
| Total Return to Investors (2016) | -7.4% |
| Total Return to Investors (5 year, annualized) | 20.8% |
| Total Return to Investors (10 year, annualized) | 19.1% |
